---
title: "midostaurin"
slug: "midostaurin"
date: "2023-05-24"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[upfront treatment of acute myelogenous leukemia (AML)]]

# midostaurin

- FLT3 çªè®Šæœƒå°è‡´ AML ç—…äººçš„ â†’ é å¾Œ âœ– ä¸è‰¯
- midostaurin æˆ ç‚ºï¼šå…¨çƒç¬¬ä¸€å€‹ä¸€ç·šæ²»ç™‚ FLT3 çªè®Šé™½æ€§ AML çš„ â†’ æ¨™é¶è—¥ç‰©ã€‚
- å°ç£ FDA ä¹Ÿæ–¼ 2018 å¹´ 4 æœˆæ ¸å‡† midostaurinï¼Œæ ¸å‡†çš„ â†’ é©æ‡‰ç—‡ ç‚ºï¼š
- æ–°ç¢ºè¨º ç‚ºï¼šFLT3 çªè®Šé™½æ€§çš„ â†’ AML æˆå¹´ç—…äººä¹‹æ¨™æº–å‰å° (daunorubicin ä½µç”¨ cytarabine) èˆ‡éå›ºæ€§åŒ–ç™‚ ï¼ˆé«˜åŠ‘é‡ cytarabineï¼‰ æ™‚åˆä½µä½¿ç”¨ã€‚

[Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation | New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa1614359)

### Midostaurin Plus Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia

**Information**

- **Design**: Phase 3, randomized, double-blind, placebo-controlled, multi-center
- **Number of patients**: 717
- **Patients characteristics**: Patients with newly diagnosed acute myeloid leukemia (AML) and a FLT3 mutation, 18 to 59 years of age
- **Agent**: Midostaurin plus standard chemotherapy vs placebo plus standard chemotherapy
- **Treatment line**: Frontline therapy
- **Trial Name or NCT Number**: NCT00651261

**Comparison of two groups**

| Endpoint            | Midostaurin + Chemotherapy                                | Placebo + Chemotherapy |
| ------------------- | --------------------------------------------------------- | ---------------------- |
| Overall Survival    | Hazard ratio for death, 0.78 (one-sided P=0.009)          | -                      |
| Event-Free Survival | Hazard ratio for event or death, 0.78 (one-sided P=0.002) | -                      |

**Other findings**

- The benefit of midostaurin was consistent across all FLT3 subtypes (ITD [high], ITD [low], and TKD)
- The rate of severe adverse events was similar in the two groups
- Allogeneic transplantation was allowed in both groups

**Summary**
In this phase 3 trial, the addition of midostaurin, a multitargeted kinase inhibitor, to standard chemotherapy significantly prolonged overall and event-free survival in patients with acute myeloid leukemia (AML) and a FLT3 mutation. The benefit of midostaurin was consistent across all FLT3 subtypes, and the rate of severe adverse events was similar in both groups.

---

- å…©çµ„å¸¸è¦‹çš„ â†’ å‰¯ä½œç”¨çš† ç‚ºï¼š
  - è²§è¡€ã€
  - å—œä¸­æ€§ç™½è¡€çƒä½ä¸‹ã€
  - è¡€å°æ¿ä½ä¸‹ã€
  - æ·‹å·´çƒæ¸›å°‘ â†“ ã€
  - å—œä¸­æ€§ç™½è¡€çƒä½ä¸‹åˆä½µç™¼ç‡’ã€
  - æ„ŸæŸ“ã€
  - è…¹ç€‰ã€
  - ä½è¡€é‰€ç­‰ï¼Œmidostaurin åŠ æ¨™æº–åŒ–ç™‚çµ„æœ‰è¼ƒå¤šè²§è¡€åŠçš®ç–¹çš„ â†’ å‰¯ä½œç”¨ (P<0.05) ã€‚
